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Objective
The objective of the study was to achieve limb salvage in patients with locally advanced
soft tissue sarcomas that can only be treated by amputation or functionally mutilating
surgery by performing an isolated limb perfusion (ILP) with tumor necrosis factor (TNF) +
melphalan (M) as induction biochemotherapy to obtain local control and make limb-sparing
surgery possible.
Summary Background Data
To increase the number of limb-sparing resections in the treatment of locally advanced
extremity soft tissue sarcoma, preoperative radiation therapy or chemotherapy or a
combination of the two often are applied. The ILP with cytostatic agents alone is another
option but rarely is used because of rather poor results. The efficacy of the application of
TNF in ILP markedly has changed this situation.
Methods
In 8 cancer centers, 186 patients were treated over a period of almost 4.5 years. There
were 107 (57%) primary and 79 (43%) recurrent sarcomas, mostly high grade (1 10 grade
III; 51 grade 11; and 25 very large, recurrent, or multiple grade sarcomas). The composition
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of this series of patients is unusual: 42 patients (23%) had multifocal primary or multiple
recurrent tumors; median tumor size was very large (16 cm); 25 patients (13%) had known
systemic metastases at the time of the ILP. Patients underwent a 90-minute ILP at 39 to
40 C with TNF + melphalan. The first 55 patients also received interferon-r. A delayed
marginal resection of the tumor remnant was done 2 to 4 months after ILP.
Results
A major tumor response was seen in 82% of the patients rendering these large sarcomas
resectable in most cases. Clinical response rates were: 33 complete response (CR) (18%),
106 partial response (PR) (57%), 42 no change (NC) (22%), and 5 progressive disease (PD)
(3%). Final outcome was defined by clinical and pathologic response: 54 CR (29%), 99 PR
(53%), 29 NC (16%), and 4 PD (2%). At a median follow-up of almost 2 years (22 months;
range, 6-58 months), limb salvage was achieved in 82%. Regional toxicity was limited and
systemic toxicity minimal to moderate, easily managed, with no toxic deaths.
Conclusions
In the setting of isolated limb perfusion, TNF is an active anticancer drug in patients. The
ILP with TNF + melphalan can be performed safely in many centers and is an effective
induction treatment with a high response rate that can achieve limb salvage in patients with
locally advanced extremity soft tissue sarcoma.
Management of locally advanced extremity soft tissue
sarcomas (STSs) that leads to an increase in preservation
of functional limbs continues to be a challenge. Although
control and prevention of distant metastases is a major
concern, limb salvage has become all the more important
in light of evidence that amputations do not improve sur-
vival rates in patients with large (>5 cm) deep-seated
high-grade sarcomas.' Local recurrence rates vary ac-
cording to the initial surgical procedure, and improved
local control has been reported to correlate with better
survival.2 Several recent studies, however, show that mar-
ginal excisions with a high risk for local recurrence do
not influence survival significantly."36 Of the 6000 new
cases of STS diagnosed in the United States each year,
approximately 3600 occur in the extremities and tumors
are often large at the time of diagnosis.7 Treatment options
for locally advanced extremity STS may consist of an
amputation or a limb-sparing extensive surgical procedure
followed by radiation therapy. This combination may mu-
tilate and compromise limb function considerably. Preop-
erative therapies to improve limb salvage rates have been
propagated. Suit et al.8 reported already in 1981 on the
use of preoperative radiation therapy. Eilber et al.9'10 com-
bined preoperative (intra-arterial or systemic) chemother-
apy and radiation therapy to improve resectability rates.
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Amputation also may be avoided and local control im-
proved by applying brachytherapy techniques to the tumor
bed in the context of marginal resections." Yet another
strategy is to perform an isolated limb perfusion (ILP)
with cytostatic agents. This technique, first described by
Creech et al.,'2 exposes tumors to drug concentrations 20
times higher than after systemic therapy'3 to maximize
tumor reduction. Melphalan, the standard drug for ILP in
the treatment of melanoma,'4 also has been used in the
treatment of extremity STS, but with rather poor re-
sults. 15-20 Doxorubicin and other drugs have been reported
to yield similar disappointing results in ILP for STS.2123
Lejeune and Lienard3s pioneered the application of tumor
necrosis factor (TNF) in ILP and reported high complete
response (CR) rates not only in patients with stage III
melanoma but remarkably also in four patients with ad-
vanced extremity STS.24 This observation led to a
multicenter study in eight centers in Europe. Here we
report on this unique experience in 186 patients with ad-
vanced extremity STS.
PATIENTS AND METHODS
Between May 1991 and November 1995, a total of 186
patients (97 men, 89 women; median age, 47 years; range,
13-82) with locally advanced extremity STS were
treated. The composition of this series of patients is un-
usual and shows that most patients were referred because
amputation was considered the only option. A total of 200
ILPs were performed in these 186 patients as 9 patients
received a second ILP within 3 months after the first ILP
to improve the initial response. Four patients underwent
a second ILP for a local recurrence, and one patient with
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Table 1. CHARACTERISTICS OF 186
PATIENTS WITH LOCALLY ADVANCED
SOFT TISSUE SARCOMAS
Characteristic
Male/female 97/89
Median age (yrs) (range) 47 (13-82)
Legs/arms 153/33
Single tumor 143 (77%)
Multiple tumors (range 2->100) 43 (23%)
Median size tumor (cm) (range) 16 (2-38)
Primary sarcomas 107 (57%)
Local recurrences 79 (43%)
Known distant metastases at time ILP 25 (13%)
ILP = isolated limb perfusion.
>100 tumors underwent a second and a third ILP for a
local (re)recurrence. Here we report on the results of the
initial treatment consisting of a single ILP in 177 patients
and of a double ILP in 9 patients. There were 107 (57%)
primary and 79 (43%) recurrent sarcomas. Sarcomas were
located in the leg in 153 and in the arm in 33 patients.
Criteria of Irresectability or Locally
Advanced Stage
All patients were referred to the eight participating can-
cer centers because the sarcomas were considered irres-
ectable or could only be resected at the cost of major
functional morbidity because of the following tumor-as-
sociated criteria: multifocal primary tumors or multiple
recurrent tumors in the limb; single tumors with fixation
to or invasion into the neurovascular bundle and/or bone;
tumor recurrences in previously radiated areas with no
possibility for a radical resection. Radical resections, that
is, resections with a margin of healthy tissue, were, based
on clinical examination and computed tomography and
magnetic resonance imaging scans, impossible in all pa-
tients. A team of specialists in the cancer centers that
all have a large sarcoma referral position agreed on the
indication for a TNF-based ILP in these patients. A single
large tumor (median size, 16 cm) was present in 143
patients (77%); in 43 patients (23%), there were multiple
lesions in the extremity (range, 2->100); 25 patients
(13%) had known systemic metastases at the time of ILP.
Patient characteristics are summarized in Table 1.
Apart from tumor-associated criteria as defined above,
inclusion and exclusion criteria included the following:
age, 12 to 80; patient informed consent, patients must
have no severe cardiopulmonary disease, no uncontrolled
infections, no organ transplants, no concurrent immuno-
suppressive therapy, no concurrent chemotherapy, immu-
Table 2. HISTOLOGIC TYPES OF SOFT
TISSUE SARCOMAS IN 186 PATIENTS
Type of Sarcoma n
Malignant fibrous histiocytoma (MFH) 47
Liposarcoma 36
Synoviosarcoma 27
Leiomyosarcoma 13
Malignant schwannoma 13
Angiosarcoma (hemangio/lymphangio) 10
Rhabdomyosarcoma 7
Fibrosarcoma 6
Clear cell sarcoma 5
Neurofibrosarcoma 4
Epithelioid sarcoma 4
Desmoid tumors 4
Neurogenic sarcoma 2
Hemangiopericytoma 2
Alveolair MFH 1
Extraosseous Ewing sarcoma 1
Chondro soft tissue sarcoma 1
Soft tissue osteosarcoma 1
Kaposi sarcoma 1
Unclassified sarcoma 1
Total 186
notherapy, radiation therapy, no coagulation disorder, no
severe obliterative peripheral arteriosclerosis, no severe
lymphedema in the extremity.
Histologic Type and Grade of Sarcomas
There were 20 different histologic types that are sum-
marized in Table 2. Tumor grading data are summarized
in Table 3. Most (161/186) tumors were high grade tu-
mors (1 10 grade III, 51 grade II), and there were 25 grade
I sarcomas (always very large, recurrent, or multiple);
Grading was according to Trojani et al.25 In brief, summa-
tion of the scores of the three most important histopatho-
logic characteristics of the tumor determines grading as
follows: 1) mitosis count at G X 400/10 fields: 0 to 9,
score 1; 10 to 20, score 2; and >20, score 3; 2) tumor
differentiation: well, moderately, or poorly differentiated
Table 3. HISTOLOGIC GRADING OF SOFT
TISSUE SARCOMAS IN 186 PATIENTS
Grade n
25
11 51
III 110
Total 186
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corresponds with scores 1, 2, and 3, respectively; 3) tumor
necrosis: no, <50%, and >50% necrosis corresponds
with scores 0, 1, and 2, respectively. Grade I has a total
score of 2 or 3, grade II has a total score of 4 or 5, and
grade III has a total score of 6, 7, or 8.
Drugs and Treatment Schedule
Recombinant human TNF-a (TNF, 0.2 mg/ampule,
4.9-5.8 x 107 units/mg) and recombinant human inter-
feron-gamma (IFN, 0.2 mg or 1.5 x 106 units/ampule)
were a gift from Boehringer Ingelheim GmbH, Ingelheiml
Rhein, Germany. Melphalan (L-Pam, Alkeran, Wellcome
Ltd., London, UK) was obtained as a sterile powder (100
mg) that was dissolved aseptically using solvent and dilu-
ent provided by Burroughs Wellcome (London, England).
Only the first 55 patients also received 0.2 mg IFN subcu-
taneously on the 2 days before the ILP and the same dose
in the perfusion circuit. As IFN has some toxicity in terms
of fever, headaches, nausea, myalgia, and arthralgia and
was not believed to be an essential component of the
treatment (see discussion section), it was left out of the
protocol after the first 55 patients. The ILP was carried
out under general anesthesia and took normally 4 to 5
hours. Isolated limb perfusion procedures have been stan-
dardized in all centers, and all centers have been visited
as part of an internal quality control program. Briefly,
isolation of the blood circuit of a limb was achieved by
clamping the major artery and vein, by ligating the collat-
eral vessels, and by applying a tourniquet to compress the
remaining minor vessels in cutis, subcutis, and muscles.
Perfusion was carried out at the axillary, brachial, iliac,
femoral, or femoropopliteal level. To obtain the proximal
(axillary or iliac) isolation level, a pin was inserted into
the head of the humerus or iliac crest; an occluding rubber
bandage was fixed around the pin and twisted around the
root of the extremity. To obtain the distal (brachial or
femoropopliteal) isolation level, an inflatable tourniquet
was used. The ILP consisted of a 90-minute long perfu-
sion, 3 (arm) to 4 (leg) mg TNF, and 10 mg/L leg or 13
mg/L arm volume of melphalan at mild hyperthermia
(39-40 C). Composition of the perfusate included the
following: priming volume of 700 to 850 mL consisted
of 400 to 500 mL blood (50% erythrocytes, 50 plasma),
200 to 400 mL 5% dextran 40 in glucose 5% (Isodex,
Pharmacia, Uppsala, Sweden) of Haemaccel (Behring
Pharma, Amsterdam, The Netherlands), 10 to 30 mL 8.4%
sodium bicarbonate, and 0.5 mL 2500 to 5000 interna-
tional units heparin. The TNF was injected as a bolus
into the arterial line provided limb tissue temperature was
>38 C. Melphalan was administered 30 minutes later at
limb temperatures between 39 and 40 C. At the end of
ILP, the limb was washed with at least 1 L of Haemaccel
and 1 L of 6% dextran 70 (Macrodex, Pharmacia, Upp-
sala, Sweden). Flow rates during the perfusion were kept
at physiologic levels of 40 to 50 mL/minute/L limb vol-
ume. Flow rates could be adjusted (reduced) in the case
of slow leakage from the limb-perfusion circuit to the
systemic compartment provided oxygen saturation levels
in the perfusate remained adequate (>65%). Perfusate
blood gas levels were monitored continuously for oxygen
saturation. Every 30 minutes, PO2 and partial pressure of
carbon dioxide (pCO2) levels were checked as well as
lactate levels and the pH, which was kept at a pH >7,25
by adding sodium if necessary. There was continuous
monitoring of the temperature in the subcutaneous and
intramuscular distal and proximal compartments of the
limb using thermistor needle probes.
Leakage Monitoring
During limb perfusion, there was a dynamic balance
between two pressure compartments, the systemic vascu-
lature and the isolated circuit, which could be influenced
by adjusting the systemic blood pressure or the extracor-
poreal flow rate or both. Throughout the perfusion period,
any potential leakage of the drugs was monitored using
a radioactive tracer. A small calibration dose of human
serum albumin radiolabelled with 1311 or 99mTc was in-
jected into the systemic circulation and a (tenfold) higher
dose of the same isotope into the isolated extremity. Con-
tinuous monitoring was performed with a precordial scin-
tillation probe. Systemic leakage was expressed quantita-
tively as a percentage (100% leakage representing a ho-
mogeneous distribution of the isotope in the body).26
Cardiopulmonary and Hemodynamic
Monitoring
Perioperative monitoring consisted in the early phase
of the study of electrocardiogram, urine output, blood
pressure, venous and pulmonary pressures, and arterial
wedge pressures. This was later only done in high-risk
patients. Similarly, the routine administration of low-dose
dopamine perioperatively was abandoned. Fluid loading
was applied during the operation before releasing the tour-
niquet after completion of the washout of the limb.
Assessment of Tumor Response
Clinical responses were as follows: Complete remis-
sions (CR: disappearance of all measurable disease in the
limb for >4 weeks), partial remissions (PR: regression
of the tumor size by more than 50% for >4 weeks), no
change (NC: regression less than 50% of the tumor in the
limb or progression less than 25% for >4 weeks), and
progressive disease (PD: progression more than 25%)
were assessed by standardized World Health Organization
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criteria.27 Extensive histopathologic examinations of the
resected specimens were performed. The percentage of
necrosis was estimated on the basis of macroscopic evalu-
ation of necrotized tissue and histologic examination re-
sults of tissue surrounding the necrotic area, tissue with-
out identifiable nuclei being considered necrotic. If clini-
cally no tumor was detectable anymore (clinical CR) but
resection of the tumor bed showed vital tumor cells, the
final outcome was downgraded to a PR. A clinical PR
could only be upgraded to a CR if histologic analysis
showed 100% necrosis of the tumor remnant. Likewise,
a clinical minimal regression of <50%, but still rendering
the tumor resectable, could be upgraded to a PR if the
tumor remnant was found to be necrotic for 50% or more.
A clinical regression of >50% would qualify for a PR
even if necrosis in the tumor remnant would be <50%,
as >50% of the tumor mass had disappeared.
Marginal Resection of the Tumor
Remnant
Resections of the tumor remnants were performed be-
tween 4 and 24 weeks after ILP (average of 10 weeks).
Usually this period allowed for enough shrinkage of the
tumor to become mobile or shrink for more than 50%.
The least of margins usually was not more than 1 mm,
and all resections were marginal resections ("shell out"
procedures). Tumors usually were still large, but after
ILP, were often surrounded by a thickened fibrous capsule
bordering on bone or neurovascular structures.
Assessment of Toxicity
Systemic toxicity was graded by the Eastern Coopera-
tive Oncology Group-World Health Organization grad-
ing.27 Regional toxicity was graded according to Wieber-
dink et al.28: 1 = no toxicity, 2 = redness and slight
edema, 3 = considerable erythema or edema with some
blistering; slightly disturbed mobility possible, 4 = exten-
sive epidermolysis or obvious damage to the deep tissues,
causing definite functional disturbances; threatening or
manifest compartmental syndrome, and 5 = reaction re-
quiring amputation.
The protocol was approved by all local ethical commit-
tees. Informed consent was obtained from all patients
before treatment.
RESULTS
Tumor Response and Limb Salvage
A major tumor response was seen in 82% of the pa-
tients, rendering most of these large sarcomas resectable.
The key parameters defining outcome of treatment, clini-
Table 4. OUTCOME OF TREATMENT IN
186 PATIENTS*
Clinical Response Histologic Response Final Outcome
(n = 186) (% necrosis) (n = 148) (n = 186)
33 CR (18%)
106 PR (57%)
42 NC (22%)
5 PD (3%)
48 CR
73 PR
27 NC
38 ND
54 CR (29%)
99 PR (53%)
29 NC (16%)
4 PD (2%)
ND = not done; CR = complete response; PR = partial response; NC = no
change; PD = progressive disease.
Limb salvage at median follow-up of 22 mo, 152/186 = 82%.
*Clinical response: CR 100% regression; PR > 50% regression; NC < 50%
regression; PD progression. Pathologic response: CR 100% necrosis; PR 50-
99% necrosis; NC <50% necrosis.
cal and pathologic response, final outcome of treatment,
and limb salvage rate are summarized in Table 4. Clinical
response rates were as follows: 33 CR (18%), 106 PR
(57%), 42 NC (22%), and 5 PD (3%). Final outcome as
defined by clinical and pathologic response was as fol-
lows: 54 CR (29%), 99 PR (53%), 29 NC (16%), and 4
PD (2%). At a median follow-up of almost 2 years (22
months) (range, 6-58 months), limb salvage was
achieved in 82% (152 patients). In 126 patients with a
single tumor, the tumor remnant was resected and a local
recurrence developed after 3 to 24 months in 14 patients
(11%). In the other 60 patients, no resection was per-
formed (multiple tumors, systemic metastases, refusal to
be amputated), local tumor control was obtained in 33
patients (55%), and recurrences occurred in 27 patients
(45%). Limb salvage often was still achieved as patients
were already dying of systemic disease. Additional radia-
tion therapy was given in only 39 (21%) of 186 patients.
Repeat Perfusions
Nine patients underwent two perfusions, scheduled 6
to 10 weeks from each other to convert a PR (or NC)
into a better response. In six patients, a PR was converted
into an CR; in two patients, a PR into a better PR, and
in one patient, NC remained NC. Four patients had a
second limb perfusion for a local recurrence 12 to 18
months after the first ILP + resection. One patient with
>100 tumors in her left forearm, wrist, and hand under-
went three perfusions at intervals of 1.0 to 1.5 years be-
cause of locally recurrent disease after a CR and long-
lasting PR.
Amputations
In 34 patients (18%), the limb had to be amputated.
Four patients underwent an amputation despite having a
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histologically confirmed CR. One patient had to be ampu-
tated early because of necrosis of a previously heavily
irradiated foot and another because tumor involvement of
the lower leg was so extensive that after resection of all
the necrosis, there was no tissue left to have a viable
lower leg. There were two late amputations: in one patient
in whom after delayed resection of a 100% necrotic tumor
mass developed osteomyelitis because of a period of inad-
equate soft tissue coverage of the bone ending in a patho-
logic fracture 17 months after ILP; the second patient
underwent an amputation 21 months after ILP despite a
CR but due to recurrent ulceration and erysipelas after
adjuvant irradiation. All other amputations were done be-
cause of insufficient response to the ILP or because of
local tumor recurrence 4 to 24 months after ILP.
Systemic Metastasis and Survival
In 25 patients (13%), synchronous metastases were
present at the time of ILP; limb salvage was achieved in
23 patients (92%) and 20 patients (80%) have died (me-
dian, 9 months); at a median follow-up of almost 2 years,
metachronous distant metastases appeared after ILP in 58
(36%) of 161 patients; 44 (27%) of these 58 patients have
died (44/58 = 76%).
Regional Toxicity
Regional toxicity was scored according to Wieberdink
et al.28 and found to be moderate. Almost all patients (171
patients) had a perfusion reaction grade II and III. This is
similar to the toxicity observed after ILP with melphalan
alone. Grade IV toxicity developed in 14 patients. In one
patient, grade V toxicity required amputation of an irradi-
ated foot. Transient paraesthesia (fingertips, toes) oc-
curred in 20% of the patients. Transient motor neura-
praxia of less than 6 months was observed in 8% and
long-lasting motor-neurapraxia (mostly peroneal nerve)
was observed in 3%.
Systemic Toxicity
Systemic toxicity was moderate and easily manageable.
Almost all patients had fever, sometimes with chills,
within 4 hours of the ILP, treated effectively with paracet-
amol or indomethacin. The following events were re-
viewed and did not require therapeutic interventions:
1. Cardiovascular. A hyperdynamic state developed in
most patients and went through a phase of slightly
lowered blood pressure, easily managed by adminis-
tering fluid and not requiring the administration of
vasopressor drugs. A significant transient drop in
blood pressure (grades III-IV) occurred in six pa-
tients (3%).
2. Pulmonary. Adult respiratory distress syndrome oc-
curred in only one patient (0.5%).
3. Renal. Creatinine levels remained normal in most
patients, but one patient experienced transient grade
IV renal toxicity (0.5%).
4. Hepatic. Hepatic toxicity was very modest and
mainly reflected in an isolated transient rise in trans-
aminases. Grade III and IV peak levels of the aspar-
tate transaminase and alanine transaminase were
seen in 17 patients (9%).
5. Hematologic. Transient grades III and IV leukope-
nia occurred in six patients and grade III and IV
thrombocytopenia occurred in eight patients (usu-
ally around day 3).
DISCUSSION
This report on our multicentric experience with TNF-
based isolated limb perfusions in the management of lo-
cally advanced extremity STS in 186 patients represents
by far the largest experience in the world.
The 29% CR rate, 53% PR rate, and the 82% limb
salvage rate at a median follow-up of almost 2 years in
this group of patients with unusually advanced disease
(median size, 16 cm; multiple tumors in 23%) show the
efficacy of this two-step approach to achieve limb salvage.
It is hard to find comparable series of patients with
comparably advanced tumors. Krementz et al.15 described
in 39 patients with extremity STS (resectable, smaller
median size) only 4 CRs (10%) and 8 PRs (21%) after
ILP with melphalan ± nitrogen mustard ± actinomycin-
D. In 17 patients with irresectable sarcomas and a delayed
resection after ILP, 0 CR (0%) and only 6 PRs (35%)
were observed.'5 These results are quite inferior to ours.
Most reports on the use of ILP in STS concern adjuvant
ILPs.'6-'9 For sarcomas, ILP with doxorubicin may seem
attractive, but its use was reported to cause considerable
regional toxicity and to be ineffective when used
alone.202' In a series of 26 patients, a 0% response rate
was seen in 22 grade II and III sarcomas with 3 amputa-
tions because of toxicity, whereas 4CRs were observed
only in patients with low grade sarcomas and only when
doxorubicin was combined with melphalan.2' In a recent
study, >50% necrosis in STS tumors after ILP with doxo-
rubicin was observed in 16 of 23 patients, but no clinical
response data were provided and, more importantly, no
complete remissions were observed.22 Others reported
high local recurrence rates and amputation rates up to
41% after ILP with melphalan in combination with other
cytostatic agents.23 Overall, it seems fair to conclude that
the addition of TNF markedly improves results and con-
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clude, thereby, that TNF is active and apparently a crucial
agent in this application in humans.
Other multimethod approaches such as the combination
of preoperative intra-arterial infusions with doxorubicin
and radiation therapy after resection of the STS also may
result in excellent local control rates, but these are
achieved in rather unselected and, thus, differently com-
posed patient populations.9"0 Again, publications on pa-
tients with disease as advanced as in this series are very
hard to find. A recent publication on this preoperative
approach by Wanebo et al.29 illustrates this point, as in
their series of 66 patients, median tumor size was only 7
cm (versus 16 cm), and local wide resections (margins
of 2-4 cm of normal tissue) were possible in 58%,
whereas these wide resections were not possible in our
patients. Other approaches to increase limb salvage are
preoperative radiation therapy,8 marginal resections in
combination with brachytherapy,'" and neoadjuvant che-
motherapy.30 Suit et al.8 reported on a favorable outcome
using preoperative radiation therapy followed by limb-
sparing surgery. Tumors were, however, smaller than in
our series. Induction chemotherapy was reported to yield
a 6% CR and a 32% PR rate by Rouesse et al.30 These
results clearly seem inferior to the results achieved by
TNF-based ILP. Shiu et al." reported on the quite suc-
cessful brachytherapy program at the Memorial Sloan
Kettering Hospital. With a 70% local control rate in pa-
tients with sarcomas abutting the neurovascular bundle,
their results may resemble the efficacy reported by us
using TNF-based ILP. Obviously, only a randomized trial
comparing the various approaches would give an answer
as to which methods are most appropriate and in which
patients. The ILP with TNF + melphalan seems of partic-
ular palliative value in the patients with widespread meta-
static disease and an uncontrollably rapidly growing tu-
mor, threatening the limb. In all but 2 of 25 of such
patients, a single ILP provided rapid and life-lasting (up
to >2 years) local control.
The local recurrence rate of 11% in 126 patients with
a single tumor and a delayed resection is low considering
the following: large median tumor size, the percentage of
recurrent sarcomas treated, and the conservative surgical
procedures, followed only in 21% of the patients by addi-
tional radiation therapy. These patients had microscopi-
cally irradical resections. Because of the size of the irradi-
ation field and/or the involvement of knee or elbow joints,
irradiation in many patients was not added to the perfu-
sion and delayed resections for the fear of inflicting too
much local toxicity and functional damage. Local recur-
rence rates probably can be further improved by giving
postresection radiation therapy in a higher percentage of
cases. In addition to histopathologic examinations, new
techniques such as magnetic resonance spectroscopy and
positron emission tomography scanning may be quite use-
ful to assess the extent of necrosis and predict the quality
of the response and, thus, influence clinical decision mak-
ing regarding type and timing of the resection of the
tumor as well as the decision to add radiation therapy.31'32
Recurrence rates were high in the 60 patients who did not
undergo a delayed resection for reasons such as multiple
tumors, pre-existing metastases, and metachronous metas-
tasis, but local control in most cases was sufficient to be
overtaken by rapid progression of systemic disease.
Our experience further shows that the procedure is safe
and is associated with only little-to-moderate regional and
systemic toxicity. Systemic toxicity is related to the leak-
age rate during the perfusion, and continuous leakage
monitoring, as described, is mandatory to perfuse safely
and be able to take corrective measures during the perfu-
sion.3334 Toxicity can be further reduced by prolonging
the washout procedure at the end of the ILP.35
The publication of a small series of TNF + melphalan
ILPs by Hill et al.36 is important in two respects: first, no
IFN-r was used and a 100% CR rate was observed in nine
patients with soft tissue sarcoma; second, lower doses of
TNF were used. The TNF levels in the perfusate varied
from 0.5 to 0.75 jLg/mL, which is approximately fivefold
to sixfold lower than the levels usually observed in the
perfusates in our trial (3-5 ,ug/mL). This suggests that
lower doses of TNF-a than used by us can be applied
successfully. It is of importance to note, however, that
also TNF concentrations of 0.50 to 0.75 ,tg/mL can only
be obtained by ILP techniques. It will add obviously to
the safety of the procedure if one can reduce the dose of
TNF while retaining its antitumor effects. In our experi-
ence, IFN--r does not seem to add to the antitumor effect
of the procedure. The response and limb salvage rates in
the first 55 patients were virtually identical to what has
been observed in the following 131 patients treated with-
out IFN, whereas systemic toxicity was somewhat more
pronounced when IFN was used.37 The nonessential role
of IFN also has been observed in a randomized phase II
study in patients with locally advanced melanoma that
we have carried out.38 Also in this study, more toxicity
was observed in the IFN containing treatment arm. In a
nonimmunogenic soft tissue sarcoma model in rats,39 we
addressed also the question of the value of IFN and did
not find enhancement of the antitumor effects compared
to after ILP with TNF + melphalan but without IFN
(Eggermont AMM, Rotterdam, personal communication,
Cambridge Symposium, TNF and Related Cytokines,
March 1996). It is clear that melphalan is crucial as ILPs
with TNF-a alone do not induce any or only very short-
lived responses in patients with melanoma,40 in patients
with STS (Fraker DL, NCI Surgery Branch, Bethesda,
MD, personal communication, Cambridge Symposium,
TNF and Related Cytokines, March 1996). In isolated
limb perfusion models in different strains of rats using
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soft tissue sarcomas394' or osteosarcomas," it has been
shown recently by the Rotterdam perfusion group that
both melphalan and TNF are crucial to obtain antitumor
effects, each agent alone being ineffective.
In contrast to the disappointing results of the systemic
administration of TNF in humans in phase I and II tri-
als,43-45 TNF may be applied successfully in humans in
a setting where the tumor and tumor vascular bed can be
exposed to very high concentrations. Apart from direct
antitumor effects,4647 TNF also has in humans mainly
important indirect (vascular) antitumor effects such as
thrombocyte aggregation, erythrostasis, endothelial, and
vascular destruction as have been described by us.48-50
These observations resemble many of the phenomena re-
ported in experimental tumor systems.51'52 These selective
vasodestructive effects on tumor vessels can be shown
elegantly by pre- and post-ILP angiographies.53 Neutro-
phils also may play an important role in the antitumor
effects as extravasation and invasion of the tumor by
neutrophils can be observed after ILP with TNF-a.48 Ob-
servations in the sarcoma perfusion model in rats in our
laboratory suggest strongly that both neutrophils and
platelets play a crucial role as much of the TNF antitumor
effect is lost in rats with severe radiation-induced neutro-
penia.54 The evidence that the common denominator, that
is, the tumor vascular bed, is the target for TNF would
predict that any histologic type of solid tumor is prone
to be sensitive to the effects of TNF. This is exactly our
experience as we have observed tumor responses in 20
types of sarcomas, melanomas, as well as in a range of
other tumors in extremities (unpublished observations,
1991-1996). Thus, TNF eventually may be used success-
fully in a number of settings such as isolated lung,55
liver,56'57 or kidney58 perfusions in the treatment of a vari-
ety of tumors.
CONCLUSIONS
The ILP with TNF + melphalan is a new option in
the management of locally advanced and irresectable soft
tissue sarcomas of the extremities. The procedure is safe
and is associated with a high response rate and a high limb
salvage rate. It merits further evaluation in an increasing
number of centers that deal with the treatment of soft
tissue sarcomas to further define its value and place in
the management of extremity tumors.
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Discussion
PROFESSOR N. S. WILLIAMS (Whitechapel, United Kingdom):
I found this paper very interesting, but you used hyperthermia
as well as a combination of TNF melphalan, and it is difficult
to understand why you are so confident that it is the TNF that
is having the effect, because hyperthermia alone is known to
